No Detail Found!

Remazolam reduces the activation of hepatic stellate cells by inactivating NOD-like receptor family pyrin domain containing 3/caspase-1/gasdermin D pathway

Author(s)
Jimin He Department of Anesthesiology, Beijing Shijitan Hospital affiliated to Capital Medical University,Beijing,China
Run Wang Department of Anesthesiology, Beijing Shijitan Hospital affiliated to Capital Medical University,Beijing,China
Pengfei Liu Department of Anesthesiology, Beijing Shijitan Hospital affiliated to Capital Medical University,Beijing,China
Yanting Hu Department of Anesthesiology, Beijing Shijitan Hospital affiliated to Capital Medical University,Beijing,China
Hui Qiao Department of Anesthesiology, Beijing Shijitan Hospital affiliated to Capital Medical University,Beijing,China
Abstract
Liver fibrosis (LF) is a progressive pathological process driven by hepatic stellate cell (HSC) activation. This study aimed to explore the effect of remazolam (RE), a benzodiazepine anesthetic, on HSC activation and its underlying mechanisms. LX-2 cells were stimulated with lipopolysaccharide (LPS) and treated with various RE concentrations. Cell viability was assessed by CCK-8 assay, and the expression of fibronectin, collagen I, and a-SMA was analyzed via western blot. Pyroptosis was evaluated by morphological observation, LDH release, ELISA for IL-1ß/IL-18, and protein expression in the NLRP3/Caspase-1/GSDMD pathway. Rescue experiments were performed by overexpressing NLRP3. RE dosedependently reduced LX-2 cell viability and downregulated fibronectin, collagen I, and a-SMA expression. RE also significantly inhibited pyroptosis, evidenced by reduced LDH release, decreased IL-1ß/IL-18 levels, and suppression of NLRP3, ASC, cleaved caspase-1, GSDMD-N, and IL-1ß. Overexpression of NLRP3 reversed the inhibitory effects of RE on pyroptosis and HSC activation. These findings indicate that RE alleviates LF by inhibiting HSC activation and pyroptosis through suppression of the NLRP3/Caspase-1/GSDMD pathway, highlighting its potential as a therapeutic agent for LF.
Publication Details
Page(s) 809-818
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
Liver fibrosis, Remazolam, NLRP3/caspase-1/GSDMD, pyroptosis
References
Asrani SK,Devarbhavi H,Eaton J,Kamath PS .2019 .Burden of liver diseases in the world. J. Hepatol., 70 : 151-171.
Babuta M,Morel C,de Carvalho Ribeiro M,Calenda C,Ortega-Ribera M,Thevkar Nagesh P,Copeland C,Zhuang Y,Wang Y,Cho Y,Joshi R,Brezani V,Hawryluk D,Datta AA,Mehta J,Nasser I,Szabo G .2024 .Neutrophil extracellular traps activate hepatic stellate cells and monocytes via NLRP3 sensing in alcoholinduced acceleration of MASH fibrosis. , 73 : 1854-1869.
Buakaew W,Krobthong S,Yingchutrakul Y,Potup P,Thongsri Y,Daowtak K,Ferrante A,Usuwanthim K A .2024 .Investigating the antifibrotic effects of β- citronellol on a TGF-β1-stimulated LX-2 hepatic stellate cell model. , 14 : 800.
Campana L,Esser H,Huch M,Forbes S M .2021 .Liver regeneration and inflammation: From fundamental science to clinical applications. Nat. Rev. Mol. Cell, 22 : 608-624.
Ceccarelli S,Panera N,Mina M,Gnani D,De Stefanis C,Crudele A,Rychlicki C,Petrini S,Bruscalupi G,Agostinelli L,Stronati L,Cucchiara S,Musso G,Furlanello C,Svegliati-Baroni G,Nobili V,Alisi A .2015 .LPS-induced TNF-α factor mediates proinflammatory and pro-fibrogenic pattern in nonalcoholic fatty liver disease. Oncotarget., 6 : 41434-41452.
De Carvalho Ribeiro M and Szabo G .2022 .Role of the inflammasome in liver disease. Annu. Rev. Pathol., 17 : 345-365.
Fang H,Zhang Y,Wang J,Li L,An S,Huang Q,Chen Z,Yang H,Wu J,Zeng Z J .2021 .Remimazolam reduces sepsis-associated acute liver injury by activation of peripheral benzodiazepine receptors and p38 inhibition of macrophages. Int. Immunopharmacol., 101 : 108331.
Fouts DE,Torralba M,Nelson KE,Brenner DA,Schnabl B .2012 .Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J. Hepatol., 56 : 1283-1292.
Gao X,Liu S,Tan L,Ding C,Fan W,Gao Z,Li M,Tang Z,Wu Y,Xu L,Yan L,Luo Y,Song S Y .2021 .Estrogen receptor α regulates metabolic-associated fatty liver disease by targeting NLRP3-GSDMD axismediated hepatocyte pyroptosis. J. Agric. Food. Chem, 69 : 14544-14556.
Guo H,Xie M,Zhou C,Zheng M C .2019 .The relevance of pyroptosis in the pathogenesis of liver diseases. Life. Sci., 223 : 69-73.
Hammerich L and Tacke F .2023 .Hepatic inflammatory responses in liver fibrosis. Nat. Rev. Gastroenterol. Hepatol., 20 : 633-646.
Hernaez R,Liu Y,Kramer JR,Rana A,El-Serag HB,Kanwal F HB .2020 .Model for end-stage liver diseasesodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J. Hepatol., 73 : 1425-1433.
Higashi T,Friedman SL,Hoshida Y .2017 .Hepatic stellate cells as key target in liver fibrosis. Adv. Drug. Deliv. Rev., 121 : 27-42.
Khanam A,Saleeb PG,Kottilil S PG .2021 .Pathophysiology and treatment options for hepatic fibrosis: Can It be completely cured? Cells. , 10 : 1097.
Kisseleva T,Brenner D .2021 .Molecular and cellular mechanisms of liver fibrosis and its regression. Nat. Rev. Gastroenterol. Hepatol., 18 : 151-166.
Knorr J,Wree A,Feldstein AE .2022 .Pyroptosis in steatohepatitis and liver diseases. J. Mol. Biol, 434 : 167271.
Kui L,Kim AD,Onyuru J,Hoffman HM,Feldstein AE .2024 .BRP39 regulates neutrophil recruitment in NLRP3 inflammasome-induced liver inflammation. Cell. Mol. Gastroenterol, 17 : 481-497.
Lamkanfi M,Dixit VM .2014 .Mechanisms and functions of inflammasomes. Cell., 157 : 1013-1022.
Lee A,Shirley M .2021 .Remimazolam: A review in procedural sedation. , 81 : 1193-1201.
Liu X,Lin S,Zhong Y,Shen J,Zhang X,Luo S,Huang L,Zhang L,Zhou S,Tang J .2021 .Remimazolam protects against LPS-induced endotoxicity improving survival of endotoxemia Mice. , 12 : 739603.
Liu Y,Kong X,You Y,Xiang L,Zhang Y,Wu R,Zhou L,Duan L L .2022 .S100A8-Mediated NLRP3 Inflammasome-dependent pyroptosis in macrophages facilitates liver fibrosis progression. Cells., 11 : 3579.
Lo RC,Kim H RC .2017 .Histopathological evaluation of liver fibrosis and cirrhosis regression. Clin. Mol. Hepatol, 23 : 302-307.
Kutala Marcellin P,BK Marcellin P .2018 .Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver. Int., 38(Suppl 1) : 2-6.
Mridha AR,Wree A,Robertson AAB,Yeh MM,Johnson CD,Van Rooyen DM,Haczeyni F,Teoh NC,Savard C,Ioannou GN,Masters SL,Schroder K,Cooper MA,Feldstein AE,Farrell GC .2017 .NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol., 66 : 1037-1046.
Murao A,Aziz M,Wang H,Brenner M,Wang P .2021 .Release mechanisms of major DAMPs. , 26 : 152-162.
Onoda A,Suzuki Y .2022 .A new anesthetic, remimazolam, is useful in the management of anesthesia in patients with liver cirrhosis. Case. Rep. Anesthesiol., 9268454 : .
Ran Y,Su W,Gao F,Ding Z,Yang S,Ye L,Chen X,Tian G,Xi J,Liu Z J .2021 .Curcumin ameliorates white matter injury after ischemic stroke by inhibiting microglia/macrophage pyroptosis through nf-κb suppression and NLRP3 inflammasome inhibition. Oxid. Med, : 1552127.
Shi M,Chen J,Liu T,Dai W,Zhou Z,Chen L,Xie Y .2022 .Protective effects of remimazolam on cerebral ischemia/reperfusion injury in rats by inhibiting of nlrp3 inflammasome-dependent pyroptosis. Drug. Des. Devel. Ther., 16 : 413-423.
Shojaie L,Iorga A,Dara L A .2020 .Cell Death in Liver Diseases: A review. Int. J. Mol. Sci, 21 : 9682.
Song J,Yu W,Chen S,Huang J,Zhou C,Liang H C .2024 .Remimazolam attenuates inflammation and kidney fibrosis following folic acid injury. Eur. J. Pharmacol., 966 : 176342.
Wesolowski AM,Zaccagnino MP,Malapero RJ,Kaye AD,Urman RD .2016 .Remimazolam: Pharmacologic considerations and clinical role in anesthesiology. , 36 : 1021-1027.
Xu W,Hu J,Liu W,Zhu Q,Gong X,Zhu P,Yang X,Xia R,Xue R .2021 .Remimazolan inhibits glioma cell growth and induces apoptosis through down-regulation of NF-κB pathway. IUBMB, 73 : 341-348.
Yang M,Li L M .2024 .Remimazolam attenuates inflammation in bronchopneumonia through the inhibition of NLRP3 activity by PDPK1 ubiquitination. Chem. Biol. Drug, 103 : e14438.
Zhang Y,Zhang H,Li S,Huang K,Jiang L,Wang Y .2022 .Metformin alleviates LPS-induced acute lung injury by regulating the SIRT1/NF-κB/NLRP3 pathway and inhibiting endothelial cell pyroptosis. Front, 13 : 801337.
Zhao J,Han M,Zhou L,Liang P,Wang Y,Feng S,Lu H,Yuan X,Han K,Chen X,Cheng J .2020 .TAF and TDF attenuate liver fibrosis through NS5ATP9, TGFβ1/Smad3and NF-κB/NLRP3 inflammasome signaling pathways. Hepatol. Int., 14 : 145-160.
Zhao YQ,Deng XW,Xu GQ,Lin J,Lu HZ,Chen J .2023 .Mechanical homeostasis imbalance in hepatic stellate cells activation and hepatic fibrosis. Front. Mol. Biosci, 10 : 1183808.
0

Citations

0

Downloads

68

Views